Short‐term outcomes of excisional atherectomy in lower limb arterial disease
Developments in PVD treatment have provided the clinician with greater diversity in management options. Newer modalities include laser angioplasty,5 drug‐eluting devices,6 brachytherapy7 and excisional atherectomy.8 Excisional atherectomy treats PVD via the use of an intra‐arterial blade to excise atheromatous disease from the vessel wall. Excisional atherectomy first came to prominence in the 1980s; however, initial results that compared poorly with angioplasty led to stagnation in the clinical use of atherectomy.9 Recent developments in atherectomy technology have renewed enthusiasm for this method. The TurboHawk plaque excision system (Covidien/ev3, Plymouth, MN, USA) is a directional, excisional atherectomy catheter approved by the Food and Drug Administration for use in 2011. The catheter utilizes a hub‐based rotating blade situated behind a tapered, debris‐collecting nose cone that can be directed to focus upon specific areas of diseased vessel, maximizing luminal gain while leaving no retained products.
Excisional atherectomy remains a relatively new technology with a lack of data on safety and effectiveness. The aims of this study were twofold: to evaluate excisional atherectomy in infrainguinal PVD in an Australian cohort and to assess the learning curve involved in the application of this new technology in the treatment of PVD.